Amgen2021: Advanced Solid Tumors with KRAS p.G12C Mutation - Clinical Trial
What is the Purpose of this Study?
Estamos realizando este estudio para comparar cuán seguras y efectivas son las diferentes combinaciones de medicamentos para tratar el cáncer metastásico.
Adenocarcinoma colorrectal con mutación KRAS p.G12C
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with advanced or metastatic colorectal adenocarcinoma with KRAS p.G12C mutation
- Have not received any previous therapy for metastatic disease
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
Si elige unirse a este estudio, podrá:
- Get a random assignment (like a coin flip) to 1 of 2 groups
-- One group will get the study drug combination of sotorasib, panitumumab, and FOLFIRI
-- The other group will get FOLFIRI either on its own or with another drug called bevacizumab-awwb
- Hacerse una biopsia del tumor, si es necesario
- Realizar extracciones de sangre
- Hacerse estudios de imágenes (tomografía computarizada o resonancia magnética)
Study Details
